Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 377

1.

Frontline therapy of acute promyelocytic leukemia: Randomized comparison of ATRA and intensified chemotherapy versus ATRA and anthracyclines.

Lengfelder E, Görlich D, Nowak D, Spiekermann K, Haferlach C, Krug U, Kreuzer KA, Braess J, Schliemann C, Lindemann HW, Horst HA, Schiel X, Flasshove M, Hecht A, Schnittger S, Schneider S, Wörmann B, Hofmann WK, Berdel WE, Bormann E, Sauerland C, Büchner T, Hiddemann W; German Acute Myeloid Leukemia Cooperative Group (AMLCG).

Eur J Haematol. 2018 Feb;100(2):154-162. doi: 10.1111/ejh.12994. Epub 2017 Dec 4.

PMID:
29114972
2.
3.

Multiparameter Flow Cytometry Provides Independent Prognostic Information in Patients with Suspected Myelodysplastic Syndromes: A Study on 804 Patients.

Kern W, Bacher U, Haferlach C, Alpermann T, Schnittger S, Haferlach T.

Cytometry B Clin Cytom. 2016 Nov 14. doi: 10.1002/cyto.b.21493. [Epub ahead of print] No abstract available.

4.

Feasibility of BAALC gene expression for detection of minimal residual disease and risk stratification in normal karyotype acute myeloid leukaemia.

Weber S, Haferlach T, Alpermann T, Perglerová K, Schnittger S, Haferlach C, Kern W.

Br J Haematol. 2016 Dec;175(5):904-916. doi: 10.1111/bjh.14343. Epub 2016 Sep 23.

PMID:
27662611
5.

Subtype-specific patterns of molecular mutations in acute myeloid leukemia.

Rose D, Haferlach T, Schnittger S, Perglerová K, Kern W, Haferlach C.

Leukemia. 2017 Jan;31(1):11-17. doi: 10.1038/leu.2016.163. Epub 2016 Jun 10.

PMID:
27285584
6.

Age, not therapy intensity, determines outcomes of adults with acute myeloid leukemia.

Büchner T, Krug UO, Peter Gale R, Heinecke A, Sauerland MC, Haferlach C, Schnittger S, Haferlach T, Müller-Tidow C, Stelljes M, Mesters RM, Serve HL, Braess J, Spiekermann K, Staib P, Grüneisen A, Reichle A, Balleisen L, Eimermacher H, Giagounidis A, Rasche H, Lengfelder E, Görlich D, Faldum A, Köpcke W, Hehlmann R, Wörmann BJ, Berdel WE, Hiddemann W.

Leukemia. 2016 Aug;30(8):1781-4. doi: 10.1038/leu.2016.54. Epub 2016 Mar 11. No abstract available.

PMID:
26965440
7.

Increasing intensity of therapies assigned at diagnosis does not improve survival of adults with acute myeloid leukemia.

Krug U, Berdel WE, Gale RP, Haferlach C, Schnittger S, Müller-Tidow C, Braess J, Spiekermann K, Staib P, Beelen D, Serve H, Schliemann C, Stelljes M, Balleisen L, Maschmeyer G, Grüneisen A, Eimermacher H, Giagounidis A, Rasche H, Hehlmann R, Lengfelder E, Thiel E, Reichle A, Aul C, Ludwig WD, Kern W, Haferlach T, Köpcke W, Görlich D, Sauerland MC, Heinecke A, Wörmann BJ, Hiddemann W, Büchner T.

Leukemia. 2016 Jun;30(6):1230-6. doi: 10.1038/leu.2016.25. Epub 2016 Feb 9.

PMID:
26859081
8.

BCR-ABL1-positive and JAK2 V617F-positive clones in 23 patients with both aberrations reveal biologic and clinical importance.

Martin-Cabrera P, Haferlach C, Kern W, Schnittger S, Haferlach T.

Br J Haematol. 2017 Jan;176(1):135-139. doi: 10.1111/bjh.13932. Epub 2016 Feb 5. No abstract available.

PMID:
26847954
9.

Gain of chromosome 21 or amplification of chromosome arm 21q is one mechanism for increased ERG expression in acute myeloid leukemia.

Weber S, Haferlach C, Jeromin S, Nadarajah N, Dicker F, Noël L, Zenger M, Alpermann T, Kern W, Haferlach T, Schnittger S.

Genes Chromosomes Cancer. 2016 Feb;55(2):148-57. doi: 10.1002/gcc.22321. Epub 2015 Nov 6.

PMID:
26542308
10.

Genetic characterization of T-PLL reveals two major biologic subgroups and JAK3 mutations as prognostic marker.

Stengel A, Kern W, Zenger M, Perglerová K, Schnittger S, Haferlach T, Haferlach C.

Genes Chromosomes Cancer. 2016 Jan;55(1):82-94. doi: 10.1002/gcc.22313. Epub 2015 Oct 23.

PMID:
26493028
11.

Molecular subtypes of NPM1 mutations have different clinical profiles, specific patterns of accompanying molecular mutations and varying outcomes in intermediate risk acute myeloid leukemia.

Alpermann T, Schnittger S, Eder C, Dicker F, Meggendorfer M, Kern W, Schmid C, Aul C, Staib P, Wendtner CM, Schmitz N, Haferlach C, Haferlach T.

Haematologica. 2016 Feb;101(2):e55-8. doi: 10.3324/haematol.2015.133819. Epub 2015 Oct 15. No abstract available.

12.

Long-term outcome of patients with newly diagnosed chronic myeloid leukemia: a randomized comparison of stem cell transplantation with drug treatment.

Gratwohl A, Pfirrmann M, Zander A, Kröger N, Beelen D, Novotny J, Nerl C, Scheid C, Spiekermann K, Mayer J, Sayer HG, Falge C, Bunjes D, Döhner H, Ganser A, Schmidt-Wolf I, Schwerdtfeger R, Baurmann H, Kuse R, Schmitz N, Wehmeier A, Fischer JT, Ho AD, Wilhelm M, Goebeler ME, Lindemann HW, Bormann M, Hertenstein B, Schlimok G, Baerlocher GM, Aul C, Pfreundschuh M, Fabian M, Staib P, Edinger M, Schatz M, Fauser A, Arnold R, Kindler T, Wulf G, Rosselet A, Hellmann A, Schäfer E, Prümmer O, Schenk M, Hasford J, Heimpel H, Hossfeld DK, Kolb HJ, Büsche G, Haferlach C, Schnittger S, Müller MC, Reiter A, Berger U, Saußele S, Hochhaus A, Hehlmann R; SAKK; German CML Study Group.

Leukemia. 2016 Mar;30(3):562-9. doi: 10.1038/leu.2015.281. Epub 2015 Oct 14.

13.

Additional mutations in SRSF2, ASXL1 and/or RUNX1 identify a high-risk group of patients with KIT D816V(+) advanced systemic mastocytosis.

Jawhar M, Schwaab J, Schnittger S, Meggendorfer M, Pfirrmann M, Sotlar K, Horny HP, Metzgeroth G, Kluger S, Naumann N, Haferlach C, Haferlach T, Valent P, Hofmann WK, Fabarius A, Cross NC, Reiter A.

Leukemia. 2016 Jan;30(1):136-43. doi: 10.1038/leu.2015.284. Epub 2015 Oct 14.

PMID:
26464169
14.

Array-based comparative genomic hybridization detects copy number variations with prognostic relevance in 80% of ALL with normal karyotype or failed chromosome analysis.

Mühlbacher V, Haferlach T, Kern W, Zenger M, Schnittger S, Haferlach C.

Leukemia. 2016 Feb;30(2):318-24. doi: 10.1038/leu.2015.276. Epub 2015 Oct 9.

PMID:
26449660
15.

Array CGH identifies copy number changes in 11% of 520 MDS patients with normal karyotype and uncovers prognostically relevant deletions.

Volkert S, Haferlach T, Holzwarth J, Zenger M, Kern W, Staller M, Nagata Y, Yoshida K, Ogawa S, Schnittger S, Haferlach C.

Leukemia. 2016 Jan;30(1):257-60. doi: 10.1038/leu.2015.257. Epub 2015 Sep 22. No abstract available.

PMID:
26392226
16.

Fusion of PDGFRB to MPRIP, CPSF6, and GOLGB1 in three patients with eosinophilia-associated myeloproliferative neoplasms.

Naumann N, Schwaab J, Metzgeroth G, Jawhar M, Haferlach C, Göhring G, Schlegelberger B, Dietz CT, Schnittger S, Lotfi S, Gärtner M, Dang TA, Hofmann WK, Cross NC, Reiter A, Fabarius A.

Genes Chromosomes Cancer. 2015 Dec;54(12):762-70. doi: 10.1002/gcc.22287. Epub 2015 Sep 10.

PMID:
26355392
17.

Evaluation of IDH1G105 polymorphism as prognostic marker in intermediate-risk AML.

Fasan A, Haferlach C, Eder C, Alpermann T, Quante A, Peters A, Kern W, Haferlach T, Schnittger S.

Ann Hematol. 2015 Dec;94(12):1991-2001. doi: 10.1007/s00277-015-2488-7. Epub 2015 Sep 9.

PMID:
26351014
18.

Karyotype evolution and acquisition of FLT3 or RAS pathway alterations drive progression of myelodysplastic syndrome to acute myeloid leukemia.

Meggendorfer M, de Albuquerque A, Nadarajah N, Alpermann T, Kern W, Steuer K, Perglerová K, Haferlach C, Schnittger S, Haferlach T.

Haematologica. 2015 Dec;100(12):e487-90. doi: 10.3324/haematol.2015.127985. Epub 2015 Aug 20. No abstract available.

19.

Next-generation deep-sequencing detects multiple clones of CALR mutations in patients with BCR-ABL1 negative MPN.

Jeromin S, Kohlmann A, Meggendorfer M, Schindela S, Perglerová K, Nadarajah N, Kern W, Haferlach C, Haferlach T, Schnittger S.

Leukemia. 2016 Apr;30(4):973-6. doi: 10.1038/leu.2015.207. Epub 2015 Jul 29. No abstract available.

PMID:
26220041
20.

KIT D816V and JAK2 V617F mutations are seen recurrently in hypereosinophilia of unknown significance.

Schwaab J, Umbach R, Metzgeroth G, Naumann N, Jawhar M, Sotlar K, Horny HP, Gaiser T, Hofmann WK, Schnittger S, Cross NC, Fabarius A, Reiter A.

Am J Hematol. 2015 Sep;90(9):774-7. doi: 10.1002/ajh.24075. Epub 2015 Aug 14.

21.

Rare FLT3 deletion mutants may provide additional treatment options to patients with AML: an approach to individualized medicine.

Chatain N, Perera RC, Rossetti G, Rossa J, Carloni P, Schemionek M, Haferlach T, Brümmendorf TH, Schnittger S, Koschmieder S.

Leukemia. 2015 Dec;29(12):2434-8. doi: 10.1038/leu.2015.131. Epub 2015 May 27. No abstract available.

PMID:
26012842
22.

BRCC3 mutations in myeloid neoplasms.

Huang D, Nagata Y, Grossmann V, Radivoyevitch T, Okuno Y, Nagae G, Hosono N, Schnittger S, Sanada M, Przychodzen B, Kon A, Polprasert C, Shen W, Clemente MJ, Phillips JG, Alpermann T, Yoshida K, Nadarajah N, Sekeres MA, Oakley K, Nguyen N, Shiraishi Y, Shiozawa Y, Chiba K, Tanaka H, Koeffler HP, Klein HU, Dugas M, Aburatani H, Miyano S, Haferlach C, Kern W, Haferlach T, Du Y, Ogawa S, Makishima H.

Haematologica. 2015 Aug;100(8):1051-7. doi: 10.3324/haematol.2014.111989. Epub 2015 May 22.

23.

Molecular diagnostics of myeloproliferative neoplasms.

Langabeer SE, Andrikovics H, Asp J, Bellosillo B, Carillo S, Haslam K, Kjaer L, Lippert E, Mansier O, Oppliger Leibundgut E, Percy MJ, Porret N, Palmqvist L, Schwarz J, McMullin MF, Schnittger S, Pallisgaard N, Hermouet S; MPN&MPNr-EuroNet.

Eur J Haematol. 2015 Oct;95(4):270-9. doi: 10.1111/ejh.12578. Epub 2015 May 18. Review.

PMID:
25951317
24.

Genetic variation at MECOM, TERT, JAK2 and HBS1L-MYB predisposes to myeloproliferative neoplasms.

Tapper W, Jones AV, Kralovics R, Harutyunyan AS, Zoi K, Leung W, Godfrey AL, Guglielmelli P, Callaway A, Ward D, Aranaz P, White HE, Waghorn K, Lin F, Chase A, Baxter EJ, Maclean C, Nangalia J, Chen E, Evans P, Short M, Jack A, Wallis L, Oscier D, Duncombe AS, Schuh A, Mead AJ, Griffiths M, Ewing J, Gale RE, Schnittger S, Haferlach T, Stegelmann F, Döhner K, Grallert H, Strauch K, Tanaka T, Bandinelli S, Giannopoulos A, Pieri L, Mannarelli C, Gisslinger H, Barosi G, Cazzola M, Reiter A, Harrison C, Campbell P, Green AR, Vannucchi A, Cross NC.

Nat Commun. 2015 Apr 7;6:6691. doi: 10.1038/ncomms7691.

25.

Downregulation of the Wnt inhibitor CXXC5 predicts a better prognosis in acute myeloid leukemia.

Kühnl A, Valk PJ, Sanders MA, Ivey A, Hills RK, Mills KI, Gale RE, Kaiser MF, Dillon R, Joannides M, Gilkes A, Haferlach T, Schnittger S, Duprez E, Linch DC, Delwel R, Löwenberg B, Baldus CD, Solomon E, Burnett AK, Grimwade D.

Blood. 2015 May 7;125(19):2985-94. doi: 10.1182/blood-2014-12-613703. Epub 2015 Mar 24.

26.

Minimal residual disease monitoring: a new era for childhood ALL.

Schnittger S.

Lancet Oncol. 2015 Apr;16(4):362-4. doi: 10.1016/S1470-2045(15)70123-3. Epub 2015 Mar 20. No abstract available.

PMID:
25800894
27.

The kinetics of relapse in DEK-NUP214-positive acute myeloid leukemia patients.

Ommen HB, Touzart A, MacIntyre E, Kern W, Haferlach T, Haferlach C, Tobal K, Hokland P, Schnittger S.

Eur J Haematol. 2015 Nov;95(5):436-41. doi: 10.1111/ejh.12511. Epub 2015 Mar 13.

PMID:
25605311
28.

AML with gain of chromosome 8 as the sole chromosomal abnormality (+8sole) is associated with a specific molecular mutation pattern including ASXL1 mutations in 46.8% of the patients.

Alpermann T, Haferlach C, Eder C, Nadarajah N, Meggendorfer M, Kern W, Haferlach T, Schnittger S.

Leuk Res. 2015 Mar;39(3):265-72. doi: 10.1016/j.leukres.2014.11.026. Epub 2014 Dec 16.

PMID:
25592059
29.

Multiparameter flow cytometry provides independent prognostic information in patients with suspected myelodysplastic syndromes: A study on 804 patients.

Kern W, Bacher U, Haferlach C, Alpermann T, Schnittger S, Haferlach T.

Cytometry B Clin Cytom. 2015 May-Jun;88(3):154-64. doi: 10.1002/cyto.b.21224. Epub 2015 Mar 24.

30.

Molecular profiling of myeloid progenitor cells in multi-mutated advanced systemic mastocytosis identifies KIT D816V as a distinct and late event.

Jawhar M, Schwaab J, Schnittger S, Sotlar K, Horny HP, Metzgeroth G, Müller N, Schneider S, Naumann N, Walz C, Haferlach T, Valent P, Hofmann WK, Cross NC, Fabarius A, Reiter A.

Leukemia. 2015 May;29(5):1115-22. doi: 10.1038/leu.2015.4. Epub 2015 Jan 8.

PMID:
25567135
31.

RAS signaling promotes resistance to JAK inhibitors by suppressing BAD-mediated apoptosis.

Winter PS, Sarosiek KA, Lin KH, Meggendorfer M, Schnittger S, Letai A, Wood KC.

Sci Signal. 2014 Dec 23;7(357):ra122. doi: 10.1126/scisignal.2005301.

32.

Refractory anemia with ring sideroblasts and marked thrombocytosis cases harbor mutations in SF3B1 or other spliceosome genes accompanied by JAK2V617F and ASXL1 mutations.

Jeromin S, Haferlach T, Weissmann S, Meggendorfer M, Eder C, Nadarajah N, Alpermann T, Kohlmann A, Kern W, Haferlach C, Schnittger S.

Haematologica. 2015 Apr;100(4):e125-7. doi: 10.3324/haematol.2014.119032. Epub 2014 Dec 19. No abstract available.

33.

Specific molecular mutation patterns delineate chronic neutrophilic leukemia, atypical chronic myeloid leukemia, and chronic myelomonocytic leukemia.

Meggendorfer M, Haferlach T, Alpermann T, Jeromin S, Haferlach C, Kern W, Schnittger S.

Haematologica. 2014 Dec;99(12):e244-6. doi: 10.3324/haematol.2014.113159. Epub 2014 Sep 19. No abstract available.

34.

Molecular-defined clonal evolution in patients with chronic myeloid leukemia independent of the BCR-ABL status.

Schmidt M, Rinke J, Schäfer V, Schnittger S, Kohlmann A, Obstfelder E, Kunert C, Ziermann J, Winkelmann N, Eigendorff E, Haferlach T, Haferlach C, Hochhaus A, Ernst T.

Leukemia. 2014 Dec;28(12):2292-9. doi: 10.1038/leu.2014.272. Epub 2014 Sep 12.

PMID:
25212276
35.

Analysis for loss of heterozygosity on chromosome arm 13q by STR analysis or SNP sequencing can replace analysis of FLT3-ITD to detect patients with prognostically adverse AML.

Schnittger S, Haferlach C, Kern W, Haferlach T.

Genes Chromosomes Cancer. 2014 Dec;53(12):1008-17. doi: 10.1002/gcc.22210. Epub 2014 Sep 3.

PMID:
25183446
36.

Accumulation of adverse prognostic markers worsens prognosis in chronic lymphocytic leukaemia.

Truger MS, Jeromin S, Weissmann S, Dicker F, Kern W, Schnittger S, Haferlach T, Haferlach C.

Br J Haematol. 2015 Jan;168(1):153-6. doi: 10.1111/bjh.13077. Epub 2014 Aug 19. No abstract available.

PMID:
25135300
37.

WT1 mutations are secondary events in AML, show varying frequencies and impact on prognosis between genetic subgroups.

Krauth MT, Alpermann T, Bacher U, Eder C, Dicker F, Ulke M, Kuznia S, Nadarajah N, Kern W, Haferlach C, Haferlach T, Schnittger S.

Leukemia. 2015 Mar;29(3):660-7. doi: 10.1038/leu.2014.243. Epub 2014 Aug 11.

PMID:
25110071
38.

Quantification of rare NPM1 mutation subtypes by digital PCR.

Bacher U, Dicker F, Haferlach C, Alpermann T, Rose D, Kern W, Haferlach T, Schnittger S.

Br J Haematol. 2014 Dec;167(5):710-4. doi: 10.1111/bjh.13038. Epub 2014 Jul 18. No abstract available.

PMID:
25039748
39.

Equivalence of BCR-ABL transcript levels with complete cytogenetic remission in patients with chronic myeloid leukemia in chronic phase.

Lauseker M, Hanfstein B, Haferlach C, Schnittger S, Pfirrmann M, Fabarius A, Schlegelberger B, Saußele S, Dietz CT, Erben P, Hehlmann R, Hasford J, Hochhaus A, Müller MC.

J Cancer Res Clin Oncol. 2014 Nov;140(11):1965-9. doi: 10.1007/s00432-014-1746-8. Epub 2014 Jun 22.

PMID:
24952896
40.

A robust molecular pattern for myelodysplastic syndromes in two independent cohorts investigated by next-generation sequencing can be revealed by comparative bioinformatic analyses.

Rose D, Kohlmann A, Nagata Y, Ogawa S, Haferlach C, Kern W, Schnittger S, Haferlach T.

Br J Haematol. 2014 Oct;167(2):278-81. doi: 10.1111/bjh.12971. Epub 2014 Jun 12. No abstract available.

PMID:
24925730
41.

Distinct characteristics of e13a2 versus e14a2 BCR-ABL1 driven chronic myeloid leukemia under first-line therapy with imatinib.

Hanfstein B, Lauseker M, Hehlmann R, Saussele S, Erben P, Dietz C, Fabarius A, Proetel U, Schnittger S, Haferlach C, Krause SW, Schubert J, Einsele H, Hänel M, Dengler J, Falge C, Kanz L, Neubauer A, Kneba M, Stegelmann F, Pfreundschuh M, Waller CF, Spiekermann K, Baerlocher GM, Pfirrmann M, Hasford J, Hofmann WK, Hochhaus A, Müller MC; SAKK and the German CML Study Group.

Haematologica. 2014 Sep;99(9):1441-7. doi: 10.3324/haematol.2013.096537. Epub 2014 May 16.

42.

TP53 mutations occur in 15.7% of ALL and are associated with MYC-rearrangement, low hypodiploidy, and a poor prognosis.

Stengel A, Schnittger S, Weissmann S, Kuznia S, Kern W, Kohlmann A, Haferlach T, Haferlach C.

Blood. 2014 Jul 10;124(2):251-8. doi: 10.1182/blood-2014-02-558833. Epub 2014 May 14.

43.

Velocity of early BCR-ABL transcript elimination as an optimized predictor of outcome in chronic myeloid leukemia (CML) patients in chronic phase on treatment with imatinib.

Hanfstein B, Shlyakhto V, Lauseker M, Hehlmann R, Saussele S, Dietz C, Erben P, Fabarius A, Proetel U, Schnittger S, Krause SW, Schubert J, Einsele H, Hänel M, Dengler J, Falge C, Kanz L, Neubauer A, Kneba M, Stegelmann F, Pfreundschuh M, Waller CF, Spiekermann K, Baerlocher GM, Pfirrmann M, Hasford J, Hofmann WK, Hochhaus A, Müller MC; SAKK and the German CML Study Group.

Leukemia. 2014 Oct;28(10):1988-92. doi: 10.1038/leu.2014.153. Epub 2014 May 6.

PMID:
24798484
44.

Amplification of EVI1 on cytogenetically cryptic double minutes as new mechanism for increased expression of EVI1.

Volkert S, Schnittger S, Zenger M, Kern W, Haferlach T, Haferlach C.

Cancer Genet. 2014 Mar;207(3):103-8. doi: 10.1016/j.cancergen.2014.02.010. Epub 2014 Feb 28.

PMID:
24726268
45.

Acute lymphoblastic leukemia with low hypodiploid/near triploid karyotype is a specific clinical entity and exhibits a very high TP53 mutation frequency of 93%.

Mühlbacher V, Zenger M, Schnittger S, Weissmann S, Kunze F, Kohlmann A, Bellos F, Kern W, Haferlach T, Haferlach C.

Genes Chromosomes Cancer. 2014 Jun;53(6):524-36. doi: 10.1002/gcc.22163. Epub 2014 Mar 11.

PMID:
24619868
46.

Relapse kinetics in acute myeloid leukaemias with MLL translocations or partial tandem duplications within the MLL gene.

Ommen HB, Hokland P, Haferlach T, Abildgaard L, Alpermann T, Haferlach C, Kern W, Schnittger S.

Br J Haematol. 2014 Jun;165(5):618-28. doi: 10.1111/bjh.12792. Epub 2014 Feb 24.

PMID:
24611505
47.

Cooperativity of RUNX1 and CSF3R mutations in severe congenital neutropenia: a unique pathway in myeloid leukemogenesis.

Skokowa J, Steinemann D, Katsman-Kuipers JE, Zeidler C, Klimenkova O, Klimiankou M, Unalan M, Kandabarau S, Makaryan V, Beekman R, Behrens K, Stocking C, Obenauer J, Schnittger S, Kohlmann A, Valkhof MG, Hoogenboezem R, Göhring G, Reinhardt D, Schlegelberger B, Stanulla M, Vandenberghe P, Donadieu J, Zwaan CM, Touw IP, van den Heuvel-Eibrink MM, Dale DC, Welte K.

Blood. 2014 Apr 3;123(14):2229-37. doi: 10.1182/blood-2013-11-538025. Epub 2014 Feb 12.

48.

Rare coincident NPM1 and RUNX1 mutations in intermediate risk acute myeloid leukemia display similar patterns to single mutated cases.

Fasan A, Haferlach C, Kohlmann A, Dicker F, Eder C, Kern W, Haferlach T, Schnittger S.

Haematologica. 2014 Feb;99(2):e20-1. doi: 10.3324/haematol.2013.099754. No abstract available.

49.

Tracing the development of acute myeloid leukemia in CBL syndrome.

Becker H, Yoshida K, Blagitko-Dorfs N, Claus R, Pantic M, Abdelkarim M, Niemöller C, Greil C, Hackanson B, Shiraishi Y, Chiba K, Tanaka H, Miyano S, Döhner K, Schnittger S, Henneke P, Niemeyer CM, Flotho C, Pfeifer D, Ogawa S, Lübbert M.

Blood. 2014 Mar 20;123(12):1883-6. doi: 10.1182/blood-2013-10-533844. Epub 2014 Feb 3.

50.

Association of the type of 5q loss with complex karyotype, clonal evolution, TP53 mutation status, and prognosis in acute myeloid leukemia and myelodysplastic syndrome.

Volkert S, Kohlmann A, Schnittger S, Kern W, Haferlach T, Haferlach C.

Genes Chromosomes Cancer. 2014 May;53(5):402-10. doi: 10.1002/gcc.22151. Epub 2014 Feb 3.

PMID:
24493299

Supplemental Content

Loading ...
Support Center